Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
571. |
ECCT/25/11/04 | Bifin02 and LGG® A Phase 3, randomized, double-blind, placebo-controlled trial to evaluate the effect of Bifidobacterium longum subsp. infantis DSM33361(Bifin02) administered together with Lacticaseibacillus rhamnosus GG DSM33156 (LGG®) versus placebo on weight gain in underweight infants |
Principal Investigator(s) 1. Charity Wambui Kanyoro Site(s) in Kenya 1. Moi University Clinical Research (Uasin Gishu county) 2. Kenya Medical Research Institute (KEMRI) CRDR Off Raila Odinga, Nairobi Kenya (Nairobi City county) 3. Kenya Medical Research Institute (KEMRI) Mwtapa (Kilifi county) |
19-08-2026 |
View |
572. |
ECCT/26/02/02 | REVIVE Study - JOOTRH A randomised, double blinded, placebo-controlled, multicentre trial of azithromycin prophylaxis for advanced HIV disease |
Principal Investigator(s) 1. Loice Achieng Ombajo Site(s) in Kenya 1. Jaramogi Oginga Odinga Teaching and Referral Hospital (JOOTRH) (Kisumu county) |
22-08-2026 |
View |
573. |
ECCT/26/03/01 | C1091009 Study A Phase 3, Randomized, Placebo-Controlled, Double-Blinded Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Multivalent Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Infants |
Principal Investigator(s) 1. Lucas Otieno Tina Site(s) in Kenya 1. Victoria Biomedical Research Institute Kisumu County Referral Hospital (Kisumu county) 2. KEMRI Butere Clinical Research Centre (Kakamega county) 3. Kenya Medical Research Institute Walter Reed Project (Kericho county) 4. Kenya Medical Research Institute (KEMRI) - Centre for Global Health Research (Kisumu county) |
26-08-2026 |
View |
574. |
ECCT/26/02/07 | IMPAACT 2024 Phase I/II Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age with and without HIV |
Principal Investigator(s) 1. LUCY Chepkurui Koech Site(s) in Kenya Kenya Medical Research Institute/Walter Reed Project(KEMRI/WRP) |
27-08-2026 |
View |
575. |
ECCT/25/08/09 | First-in-human (FIH) study A Phase 1, Randomized, Placebo-Controlled, Double Blind, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CLY-124 in Healthy Volunteers and Participants with Sickle Cell Disease |
Principal Investigator(s) 1. Dr Lucas Tina Otieno Site(s) in Kenya 1. Victoria Biomedical Research Institute [VIBRI] (Kisumu county) 2. Strathmore University Medical Center [SUMC], Creates for Research in Therapeutic Sciences (Nairobi City county) |
17-09-2026 |
View |
576. |
ECCT/26/02/03 | REVIVE Study - KNH A randomised, double blinded, placebo-controlled, multicentre trial of azithromycin prophylaxis for advanced HIV disease |
Principal Investigator(s) 1. Loice Achieng Ombajo Site(s) in Kenya 1. Kenyatta National Hospital (KNH) (Nairobi City county) |
28-09-2026 |
View |
577. |
ECCT/26/04/01 | ACRN-MNK02-301 A Phase 3, randomized, double-blind, placebo-controlled trial to evaluate the effect of Bifidobacterium longum subsp. infantis DSM33361(Bifin02) administered together with Lacticaseibacillus rhamnosus GG DSM33156 (LGG ®) versus placebo on weight gain in underweight infants. |
Principal Investigator(s) 1. Prof. Videlis Nduba Site(s) in Kenya 1. KEMRI-CRDR (Nairobi City county) 2. KEMRI-MTWAPA (Kilifi county) 3. Moi University Clinical Research Centre (Uasin Gishu county) |
21-10-2026 |
View |
578. |
ECCT/25/12/03 | ITU512 Study - Site 6002 A Phase I/II clinical study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ITU512 in healthy participants and patients with sickle cell disease |
Principal Investigator(s) 1. Doreen Terry Karimi Mutua Site(s) in Kenya 1. Site 6001: International Cancer Institute (Uasin Gishu county) 2. Site 6002: Gertrude’s Children’s Hospital (Nairobi City county) 3. Site 6003: KEMRI Kondele Children’s Hospital (Kisumu county) |
23-10-2026 |
View |
579. |
ECCT/25/12/02 | ITU512 Study - Site 6003 A Phase I/II clinical study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ITU512 in healthy participants and patients with sickle cell disease |
Principal Investigator(s) 1. Godfrey Allan Otieno Site(s) in Kenya 1. Site 6001: International Cancer Institute (Uasin Gishu county) 2. Site 6002: Gertrude’s Children’s Hospital (Nairobi City county) 3. Site 6003: KEMRI Kondele Children’s Hospital (Kisumu county) |
23-10-2026 |
View |
580. |
ECCT/26/03/03 | LIBRA A 52-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group, group sequential, Phase 3 study to evaluate the efficacy and safety of rilzabrutinib in patients aged 10 to 65 years with sickle-cell disease (LIBRA) |
Principal Investigator(s) 1. Jessie Githanga Site(s) in Kenya Getrudes’s Children\'s Hospital |
23-10-2026 |
View |